Silence Therapeutics Announces Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Author: Benzinga Newsdesk | March 13, 2024 07:01am

Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease (ASCVD) events. Zerlasiran is a siRNA (short interfering RNA) designed to lower the body's production of Lp(a), a key genetic risk factor for cardiovascular disease affecting up to 20% of the world's population.

Posted In: SLN